Pre-Disease Intervention: Bringing Precision Medicine from the Back End to the Front End of Diseases. We will focus on how industry perceives the current challenges in precision medicine and their outlook based on specific case studies.
Chairman and Chief Executive Officer HeritX, Santa Monica, USA
|Preventing Cancer – Turning a Challenge into Unprecedented Opportunity |
Unlike other cancers, we already know the first step in the development of BRCA cancers (the inherited BRCA mutation), can identify BRCA mutation carriers through genetic testing, and focus our unprecedented biomedical tools and technologies to medically intervene before cancer starts. In BRCA, prevention is possible. Moreover, similarities between BRCA pre-cancer and the development of other cancers will make advances in BRCA applicable to other cancers: BRCA is a gateway to cancer prevention.
Head of Biomarker Strategy, Bayer AG, Berlin, Germany
|Biomarkers in Oncology Drug Development|
Project Manager Clinical Studies, BioNTech, Mainz, Germany
Novel RNA-Based Cancer Immunotherapies
Immunotherapy has evolved as a promising alternative to conventional treatments against cancer. Vaccination with RNAs encoding for tumor-specific antigens or neo-epitopes has been shown to be capable of efficiently inducing antigen-specific T-cell responses and anti-tumor immunity. We have developed pioneering RNA-lipoplex (RNA(LIP)) immunotherapeutics for intravenous application which are currently being tested in clinical trials with promising preliminary results.
To download the full programme, click here.